Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Molecules. 2022 Mar 1;27(5):1635. doi: 10.3390/molecules27051635.
The interaction of common anticancer drug gemcitabine with human serum albumin (HSA) has been studied in detail. The effect of an omnipresent nonsteroidal anti-inflammatory drug ibuprofen was also seen on the binding of HSA and gemcitabine. A slight hyperchromic shift in the difference UV-visible absorption spectra of HSA on the addition of gemcitabine gave a primary idea of the possible complex formation between them. The inner filter effect, which happens due to the significant absorbance of the ligand at the excitation and/or emission wavelengths, played an important role in the observed fluorescence quenching of HSA by gemcitabine that can be understood by comparing the observed and corrected fluorescence intensities obtained at λ = 280 nm and 295 nm. Gemcitabine showed weak interaction with HSA, which took place via a dynamic quenching mechanism with 1:1 cooperative binding between them. Secondary structural analysis, based on circular dichroism (CD) spectroscopy, showed that low concentrations of gemcitabine did not affect the native structure of protein; however, higher concentrations affected it slightly with partial unfolding. For understanding the binding site of gemcitabine within HSA, both experimental (using site markers, warfarin and ibuprofen) as well as computational methods were employed, which revealed that the gemcitabine binding site is located between the interface of subdomain IIA and IIB within the close proximity of the warfarin site (drug site 1). The effect of ibuprofen on the binding was further elaborated because of the possibility of its coexistence with gemcitabine in the prescription given to the cancer patients, and it was noticed that, ibuprofen, even present in high amounts, did not affect the binding efficacy of gemcitabine with HSA. DFT analyses of various conformers of gemcitabine obtained from its docking with various structures of HSA (free and bounded with site markers), show that the stability of the gemcitabine molecule increased slightly after binding with ibuprofen-complexed HSA. Both experimental as well as computational results were in good agreement with each other.
研究了常见抗癌药物吉西他滨与人血清白蛋白(HSA)的相互作用。还观察了一种普遍存在的非甾体抗炎药布洛芬对 HSA 与吉西他滨结合的影响。在加入吉西他滨后,HSA 的差示紫外-可见吸收光谱略微增色,这初步表明它们之间可能形成了复合物。由于配体在激发和/或发射波长处有很大的吸光度,内滤效应在吉西他滨对 HSA 的荧光猝灭中起重要作用,可以通过比较在 λ = 280nm 和 295nm 处获得的观察到的和校正后的荧光强度来理解。吉西他滨与 HSA 表现出微弱的相互作用,这是通过它们之间的动态猝灭机制发生的,结合比为 1:1 协同。基于圆二色性(CD)光谱的二级结构分析表明,低浓度的吉西他滨不会影响蛋白质的天然结构;然而,较高浓度的吉西他滨会对其产生轻微影响,导致部分展开。为了了解吉西他滨在 HSA 中的结合位点,同时使用实验(使用位点标记物华法林和布洛芬)和计算方法,结果表明吉西他滨的结合位点位于亚域 IIA 和 IIB 之间的界面附近,靠近华法林结合位点(药物结合位点 1)。由于布洛芬可能与吉西他滨共存于癌症患者的处方中,因此进一步阐述了布洛芬对结合的影响,并且注意到即使在高浓度下,布洛芬也不会影响吉西他滨与 HSA 的结合效力。通过对吉西他滨与 HSA 的各种结构(游离和结合位点标记物)进行对接得到的各种构象进行 DFT 分析,表明吉西他滨分子与结合有布洛芬的 HSA 结合后稳定性略有增加。实验和计算结果相互吻合较好。